BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
- Study will assess bemcentinib in combination with current standard of care for 1st line NSCLC - - Approximately 20% of NSCLC patients have STK11 mutations - - First patient is expected to be dosed in 4Q22 - BERGEN, Norway, October 11, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the initiation of a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, checkpoint inhibitor pembrolizumab and doublet chemotherapy,